Molecular Characterization of Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: Implications for Immunotherapy.
作者信息
Singh Priya, Gupta Parul, De Arka, Duseja Ajay
机构信息
Departments of Hepatology, Post-graduate Institute of Medical Education and Research, Chandigarh, India.
Departments of Pathology, Post-graduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1140-1143. doi: 10.1016/j.jceh.2023.03.001. Epub 2023 Nov 2.
Abstract
摘要
相似文献
1
Molecular Characterization of Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: Implications for Immunotherapy.非酒精性脂肪性肝炎中肝细胞癌的分子特征：对免疫治疗的意义。
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1140-1143. doi: 10.1016/j.jceh.2023.03.001. Epub 2023 Nov 2.
2
Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.利用高脂、胆碱缺乏饮食和腹腔注射二乙基亚硝胺建立一种伴有非酒精性脂肪性肝炎的新型肝细胞癌小鼠模型。
BMC Gastroenterol. 2016 Jun 13;16(1):61. doi: 10.1186/s12876-016-0477-5.
3
Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey.非酒精性脂肪性肝炎与肝细胞癌：巴西调查
Clinics (Sao Paulo). 2016 May;71(5):281-4. doi: 10.6061/clinics/2016(05)07.
4
State of CD8 T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy.非酒精性脂肪性肝炎向肝细胞癌进展过程中 CD8+T 细胞的状态：从发病机制到免疫治疗。
Biomed Pharmacother. 2023 Sep;165:115131. doi: 10.1016/j.biopha.2023.115131. Epub 2023 Jul 8.
5
Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.非酒精性脂肪性肝炎相关肝细胞癌的手术意义
Cancers (Basel). 2024 Aug 6;16(16):2773. doi: 10.3390/cancers16162773.
6
[Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis].
Gastroenterol Clin Biol. 2004 May;28(5):497-9. doi: 10.1016/s0399-8320(04)94971-8.
7
Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience.非酒精性脂肪性肝炎相关肝细胞癌的切除术：西方经验
Int J Surg Oncol. 2012;2012:915128. doi: 10.1155/2012/915128. Epub 2012 Sep 4.
8
Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.非酒精性脂肪性肝病与非酒精性脂肪性肝炎：病理与临床意义。
Curr Vasc Pharmacol. 2018;16(3):214-218. doi: 10.2174/1570161115666170621075157.
9
Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma.非酒精性脂肪性肝炎及其向肝细胞癌转变的炎症机制
Cancers (Basel). 2021 Feb 10;13(4):730. doi: 10.3390/cancers13040730.
10
The Role of CD4T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.CD4T 细胞在非酒精性脂肪性肝炎和肝细胞癌中的作用。
Int J Mol Sci. 2024 Jun 23;25(13):6895. doi: 10.3390/ijms25136895.
本文引用的文献
1
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
2
Immunotherapies for hepatocellular carcinoma.肝细胞癌的免疫疗法
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11.
3
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.非酒精性脂肪性肝炎患者肝细胞癌的分子特征。
J Hepatol. 2021 Oct;75(4):865-878. doi: 10.1016/j.jhep.2021.04.049. Epub 2021 May 13.
4
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
7
Immune checkpoint inhibitors win the 2018 Nobel Prize.免疫检查点抑制剂荣获 2018 年诺贝尔生理学或医学奖。
Biomed J. 2019 Oct;42(5):299-306. doi: 10.1016/j.bj.2019.09.002. Epub 2019 Nov 5.
8
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.与人类肝细胞癌发展相关的免疫基因表达谱可识别对化学预防剂有反应的小鼠。
Gastroenterology. 2019 Nov;157(5):1383-1397.e11. doi: 10.1053/j.gastro.2019.07.028. Epub 2019 Jul 22.
9
From NASH to HCC: current concepts and future challenges.从 NASH 到 HCC：当前概念和未来挑战。
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7.
10
Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.非肝硬化肝脏中的肝细胞癌：全面综述
World J Hepatol. 2019 Jan 27;11(1):1-18. doi: 10.4254/wjh.v11.i1.1.
Zotero 插件